In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

F Nicoletti; P Meroni; R Di Marco; W Barcellini; M O Borghi; M Gariglio; A Mattina; S Grasso; S Landolfo

doi:10.1016/0162-3109(92)90064-j

In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

Immunopharmacology. 1992 Jul-Aug;24(1):11-6. doi: 10.1016/0162-3109(92)90064-j.

Authors

F Nicoletti¹, P Meroni, R Di Marco, W Barcellini, M O Borghi, M Gariglio, A Mattina, S Grasso, S Landolfo

Affiliation

¹ Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy.

PMID: 1452442
DOI: 10.1016/0162-3109(92)90064-j

Abstract

The effects of the in vitro treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Autoimmune Diseases / complications*
Autoimmune Diseases / pathology
Autoimmune Diseases / therapy
Disease Models, Animal
Female
Interferon-gamma / immunology
Interferon-gamma / physiology*
Lupus Erythematosus, Systemic / etiology
Lupus Erythematosus, Systemic / therapy
Lupus Nephritis / etiology*
Lymphoproliferative Disorders / complications*
Lymphoproliferative Disorders / pathology
Lymphoproliferative Disorders / therapy
Mice

Substances

Antibodies, Monoclonal
Interferon-gamma